NICE dismisses GSK's Tyverb appeal but throws off-label Herceptin lifeline
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, has dismissed GlaxoSmithKline's appeal against the institute's final draft guidance rejecting Tyverb (lapatinib) for some breast cancer patients, except in the context of clinical trials.